Immunic (IMUX)

• Market cap: $190M
• 1 day: -0.14%
• 5 days: 4.57%
• 1 month: -9.11%
• 3 months: 45.22%
• 6 months: 113.61%
• Year to date: 139.62%
• 1 year: 48.62%
• 5 years: -84.34%
• 10 years: -99.44%
• Sector: Healthcare
• Industry: Biotechnology

About: Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Employees: 95